NASDAQ:ISEE - IVERIC bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.20
  • Forecasted Upside: 76.77 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$13.69
▲ +0.31 (2.32%)

This chart shows the closing price for ISEE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New IVERIC bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ISEE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ISEE

Analyst Price Target is $24.20
▲ +76.77% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for IVERIC bio in the last 3 months. The average price target is $24.20, with a high forecast of $30.00 and a low forecast of $12.00. The average price target represents a 76.77% upside from the last price of $13.69.

This chart shows the closing price for ISEE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in IVERIC bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/2/2022UBS GroupInitiated CoverageBuy$20.00Low
7/7/2022Morgan StanleyBoost Price TargetOverweight$25.00 ➝ $30.00N/A
6/8/2022GuggenheimInitiated CoverageBuy$30.00High
6/8/2022Bank of AmericaInitiated CoverageBuy$18.00Medium
5/20/2022Credit Suisse GroupBoost Price Target$24.00High
5/12/2022B. RileyInitiated CoverageNeutral$12.00Medium
5/4/2022Stifel NicolausBoost Price Target$22.00 ➝ $28.00High
3/22/2022Jefferies Financial GroupInitiated CoverageBuy$27.00High
3/3/2022Robert W. BairdInitiated CoverageOutperform$27.00High
2/7/2022Morgan StanleyInitiated CoverageOverweight$25.00High
11/10/2021HC WainwrightBoost Price TargetBuy$20.00 ➝ $26.00High
9/13/2021HC WainwrightReiterated RatingBuy$20.00High
9/10/2021Credit Suisse GroupBoost Price TargetOutperform$15.00 ➝ $18.00High
9/10/2021Stifel NicolausInitiated CoverageBuy$22.00High
9/1/2021HC WainwrightReiterated RatingBuy$20.00Medium
8/19/2021HC WainwrightInitiated CoverageBuy$20.00High
7/6/2021Credit Suisse GroupBoost Price TargetPositive ➝ Outperform$14.00 ➝ $16.00High
8/13/2020Credit Suisse GroupInitiated CoverageOutperform$13.00High
5/25/2020WedbushReiterated RatingOutperform ➝ Market Perform$13.00Low
1/24/2020CowenInitiated CoverageOutperformLow
1/6/2020WedbushInitiated CoverageOutperformMedium
9/18/2019Chardan CapitalReiterated RatingHold$1.25Low
(Data available from 8/10/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/12/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/11/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 5 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
IVERIC bio logo
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
Read More

Today's Range

Now: $13.69
Low: $13.55
High: $13.82

50 Day Range

MA: $10.75
Low: $9.12
High: $13.38

52 Week Range

Now: $13.69
Low: $8.37
High: $19.34

Volume

9,364 shs

Average Volume

1,790,963 shs

Market Capitalization

$1.62 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Frequently Asked Questions

What sell-side analysts currently cover shares of IVERIC bio?

The following Wall Street analysts have issued research reports on IVERIC bio in the last twelve months: B. Riley, Bank of America Co., Credit Suisse Group AG, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., Morgan Stanley, Robert W. Baird, Stifel Nicolaus, StockNews.com, and UBS Group AG.
View the latest analyst ratings for ISEE.

What is the current price target for IVERIC bio?

10 Wall Street analysts have set twelve-month price targets for IVERIC bio in the last year. Their average twelve-month price target is $24.20, suggesting a possible upside of 76.8%. Morgan Stanley has the highest price target set, predicting ISEE will reach $30.00 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $12.00 for IVERIC bio in the next year.
View the latest price targets for ISEE.

What is the current consensus analyst rating for IVERIC bio?

IVERIC bio currently has 1 hold rating and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ISEE will outperform the market and that investors should add to their positions of IVERIC bio.
View the latest ratings for ISEE.

What other companies compete with IVERIC bio?

How do I contact IVERIC bio's investor relations team?

IVERIC bio's physical mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The company's listed phone number is (212) 845-8200 and its investor relations email address is [email protected] The official website for IVERIC bio is ivericbio.com. Learn More about contacing IVERIC bio investor relations.